Therapeutic Effect of Nicotinamide Mononucleotide for Hypoxic-Ischemic Brain Injury in Neonatal Mice

被引：7

作者：

Kawamura, Takuya ^{[1
,2
]}

Mallah, Gagandeep Singh ^{[1
]}

Ardalan, Maryam ^{[1
]}

Chumak, Tetyana ^{[1
]}

Svedin, Pernilla ^{[1
]}

Jonsson, Lina ^{[1
]}

Shiadeh, Seyedeh Marziyeh Jabbari ^{[1
]}

Goretta, Fanny ^{[1
]}

Ikeda, Tomoaki ^{[2
]}

Hagberg, Henrik ^{[3
]}

Sandberg, Mats ^{[4
]}

Mallard, Carina ^{[1
,5
]}

机构：

[1] Univ Gothenburg, Inst Neurosci & Physiol, Sahlgrenska Acad, Ctr Perinatal Med & Hlth, Gothenburg, Sweden

[2] Mie Univ, Dept Obstet & Gynecol, Tsu, Japan

[3] Inst Clin Sci, Ctr Perinatal Med & Hlth, Gothenburg, Sweden

[4] Univ Gothenburg, Inst Biomed, Sahlgrenska Acad, Gothenburg, Sweden

[5] Univ Gothenburg, Inst Neurosci & Physiol, Sahlgrenska Acad, Box 432, S-40530 Gothenburg, Sweden

来源：

ASN NEURO | 2023年 / 15卷

关键词：

sirtuins; alarmins; infant; therapy; hypoxic-ischemic encephalopathy; nicotinamide adenine dinucleotide; MOBILITY GROUP BOX-1; NAD(+) METABOLISM; PROTEIN SIR2; HMGB1; DAMAGE; LOCALIZATION; HYPOTHERMIA; DISRUPTION; EXPRESSION; MEDIATOR;

D O I：

10.1177/17590914231198983

中图分类号：

Q189 [神经科学];

学科分类号：

071006 ;

摘要：

A clinical challenge remains in the treatment of hypoxic-ischemic brain injury in newborns. Nicotinamide adenine dinucleotide (NAD+) has beneficial effects in animal models of adult stroke. Here, we aimed to understand the short- and long-term neuroprotective effects of NAD+-promoting substance nicotinamide mononucleotide (NMN) in a well-established brain injury model in neonatal mice. Postnatal day (PND) 9 male and female mice were subjected to cerebral hypoxia-ischemia and treated with saline or NMN (50 mg/kg) immediately after hypoxia-ischemia. At different time points after hypoxia-ischemia, hippocampal NAD+, caspase-3 activity, protein expression of SIRT1, SIRT6, release of high mobility group box-1 (HMGB1), long-term neuropathological outcome, short-term developmental behavior, and long-term motor and memory function were evaluated. Neonatal hypoxia-ischemia reduced NAD+ and SIRT6 levels, but not SIRT1, in the injured hippocampus, while HMGB1 release was significantly increased. NMN treatment normalized hippocampal NAD+ and SIRT6 levels, while caspase-3 activity and HMGB1 release were significantly reduced. NMN alleviated tissue loss in the long-term and improved early developmental behavior, as well as motor and memory function. This study shows that NMN treatment provides neuroprotection in a clinically relevant neonatal animal model of hypoxia-ischemia in mice suggesting as a possible novel treatment for neonatal brain injury.Summary StatementNeonatal hypoxia-ischemia reduces nicotinamide adenine dinucleotide (NAD+) and SIRT6 levels in the injured hippocampus.Hippocampal high mobility group box-1 (HMGB1) release is significantly increased after neonatal hypoxia-ischemia.Nicotinamide mononucleotide (NMN) treatment normalizes hippocampal NAD+ and SIRT6 levels, with significant decrease in caspase-3 activity and HMGB1 release.NMN improves early developmental behavior, as well as motor and memory function. Graphical AbstractThis is a visual representation of the abstract.

引用

页数：17

共 59 条

[41]

MERENMIES J, 1991, J BIOL CHEM, V266, P16722

[42] Long-Term Administration of Nicotinamide Mononucleotide Mitigates Age-Associated Physiological Decline in Mice [J].